Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14008-

  Sestak, Joshua O ^a   Sullivan, Bradley P ^a   Thati, Sharadvi ^a   Northrup, Laura ^a   Hartwell, Brittany ^b   Antunez, Lorena ^a   Forrest, M Laird ^a   Vines, Charlotte M ^c   Siahaan, Teruna J ^a   Berkland, Cory ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922905150     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.8     Document Type: Article

References (60)

1. Brück, W, Gold, R, Lund, BT, Oreja-Guevara, C, Prat, A, Spencer, CM et al. (2013). Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 70: 1315-1324.
2. Lucchinetti, CF, Bruck, W and Lassmann, H (2004). Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 56: 308.
3. Ransohoff, RM and Brown, MA (2012). Innate immunity in the central nervous system. J Clin Invest 122: 1164-1171.
4. Carson, MJ, Doose, JM, Melchior, B, Schmid, CD and Ploix, CC (2006). CNS immune privilege: hiding in plain sight. Immunol Rev 213: 48-65.
5. Amor, S, Puentes, F, Baker, D and van der Valk, P (2010). Inflammation in neurodegenerative diseases. Immunology 129: 154-169.
6. Wingerchuk, DM and Lucchinetti, CF (2007). Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 20: 343-350.
7. Bates, D (2011). Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 76: S14-S25.
8. Weiner, HL (2004). Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 61: 1613-1615.
9. Miller, SD, Turley, DM and Podojil, JR (2007). Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 7: 665-677.
10. Dolgin, E (2010). The inverse of immunity. Nat Med 16: 740-743.
11. Aharoni, R, Teitelbaum, D, Leitner, O, Meshorer, A, Sela, M and Arnon, R (2000). Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 97: 11472-11477.
12. Senti, G, Prinz Vavricka, BM, Erdmann, I, Diaz, MI, Markus, R, McCormack, SJ et al. (2008). Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 105: 17908-17912.
13. Steinman, L and Conlon, P (2001). Antigen specific immunotherapy of multiple sclerosis. J Clin Immunol 21: 93-98.
14. Okuno, T, Nakatsuji, Y, Moriya, M, Nojima, S, Sakoda, S, Kumanogoh, A, et al. (2010). Multiple sclerosis (PP-038) [abstr.]. Int Immunol Meeting Abstracts 22: i148-i155.
15. Kool, M, Pétrilli, V, De Smedt, T, Rolaz, A, Hammad, H, van Nimwegen, M et al. (2008). Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181: 3755-3759.
16. Ahmed, N and Gottschalk, S (2009). How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines 8: 543-546.
17. Rolland, JM, Gardner, LM and O'Hehir, RE (2009). Allergen-related approaches to immunotherapy. Pharmacol Ther 121: 273-284.
18. Lisak, RP, Zweiman, B, Blanchard, N and Rorke, LB (1983). Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 62: 281-293.
19. Vickery, BP and Burks, AW (2009). Immunotherapy in the treatment of food allergy: focus on oral tolerance. Curr Opin Allergy Clin Immunol 9: 364-370.
20. Vickery, B P, Scurlock, AM, Jones, SM and Burks, AW (2011). Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol 127: 576-584.
21. Senti, G, Crameri, R, Kuster, D, Johansen, F, Martinez-Gomez, JM, Graf, N et al. (2012). Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 129, 1290-1296.
22. Sabatos-Peyton, CA, Verhagen, J and Wraith, DC (2010). Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 22, 609-615.
23. Mossman, KD, Campi, G, Groves, JT and Dustin, ML (2005). Altered TCR signaling from geometrically repatterned immunological synapses. Science 310: 1191-1193.
24. Hartman, NC, Nye, JA and Groves, JT (2009). Cluster size regulates protein sorting in the immunological synapse. Proc Natl Acad Sci USA 106: 12729-12734.
25. Dustin, ML (2002). The immunological synapse. Arthritis Res 4(suppl. 3): S119-S125.
26. Dustin, ML and Shaw, AS (1999). Costimulation: building an immunological synapse. Science 283: 649-650.
27. Bromley, S, Iaboni, A, Davis, SJ, Whitty, A, Green, JM, Shaw, AS et al. (2001). The immunological synapse and CD28-CD80 interactions. Nat Immunol 2: 1159-1166.
28. Kobayashi, N, Kobayashi, H, Gu, L, Malefyt, T and Siahaan, TJ (2007). Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J Pharmacol Exp Ther 322: 879-886.
29. Manikwar, P, Kiptoo, P, Badawi, AH, Büyüktimkin, B and Siahaan, TJ (2012). Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Med Res Rev 32: 727-764.
30. Yusuf-Makagiansar, H, Makagiansar, IT, Hu, Y and Siahaan, TJ (2001). Synergistic inhibitory activity of alpha-and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides 22: 1955-1962.
31. Dustin, ML (2009). The cellular context of T cell signaling. Immunity 30: 482-492.
32. Sant, AJ, Chaves, FA, Jenks, SA, Richards, KA, Menges, P, Weaver, JM et al. (2005). The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol Rev 207: 261-278.
33. Dintzis, HM, Dintzis, RZ and Vogelstein, B (1976). Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci USA 73: 3671-3675.
34. Dixon, FJ and Kunkel, HG (1982). Advances in Immunology. 32: Academic Press, USA.
35. Dintzis, RZ, Okajima, M, Middleton, MH, Greene, G and Dintzis, HM (1989). The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 143: 1239-1244.
36. Reim, JW, Symer, DE, Watson, DC, Dintzis, RZ and Dintzis, HM (1996). Low molecular weight antigen arrays delete high affinity memory B cells without affecting specific T-cell help. Mol Immunol 33: 1377-1388.
37. Symer, DE, Reim, J, Dintzis, RZ, Voss, EW Jr and Dintzis, HM (1995). Durable elimination of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in vivo. J Immunol 155: 5608-5616.
38. Sestak, J, Mullins, M, Northrup, L, Thati, S, Forrest, ML, Siahaan, TJ et al. (2013). Single-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. J Control Release 168: 334-340.
39. Aranami, T and Yamamura, T (2008). Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 57: 115-120.
40. Kuchroo, VK, Greer, JM, Kaul, D, Ishioka, G, Franco, A, Sette, A et al. (1994). A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 153: 3326-3336.
41. Stern, JN, Illés, Z, Reddy, J, Keskin, DB, Fridkis-Hareli, M, Kuchroo, VK et al. (2005). Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102: 1620-1625.
42. Margot, CD, Ford, ML and Evavold, BD (2005). Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J Immunol 174: 3352-3358.
43. Samson, MF and Smilek, DE (1995). Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol 155: 2737-2746.
44. Vanderlugt, CL, Neville, KL, Nikcevich, KM, Eagar, TN, Bluestone, JA and Miller, SD (2000). Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 164: 670-678.
45. Smith, CE, Eagar, TN, Strominger, JL and Miller, SD (2005). Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102: 9595-9600.
46. Wang, C, Gold, BG, Kaler, LJ, Yu, X, Afentoulis, ME, Burrows, GG et al. (2006). Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 98: 1817-1827.
47. Johnson, KP, Brooks, BR, Cohen, JA, Ford, CC, Goldstein, J, Lisak, RP et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
48. Blanchette, F and Neuhaus, O (2008). Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 255(suppl. 1): 26-36.
49. Neuhaus, O, Farina, C, Wekerle, H and Hohlfeld, R (2001). Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56: 702-708.
50. Perrin, PJ, June, CH, Maldonado, JH, Ratts, RB and Racke, MK (1999). Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 163: 1704-1710.
51. Gerritse, K, Laman, JD, Noelle, RJ, Aruffo, A, Ledbetter, JA, Boersma, WJ et al. (1996). CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 93: 2499-2504.
52. Langer-Gould, A, Atlas, SW, Green, AJ, Bollen, AW and Pelletier, D (2005). Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.
53. Ridwan, R, Kiptoo, P, Kobayashi, N, Weir, S, Hughes, M, Williams, T et al. (2010). Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics. J Pharmacol Exp Ther 332: 1136-1145.
54. Kang, Y, Xu, L, Wang, B, Chen, A and Zheng, G (2008). Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J Immunol 180: 5172-5176.
55. Badawi, AH, Kiptoo, P, Wang, WT, Choi, IY, Lee, P, Vines, CM et al. (2012). Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor. Neuropharmacology 62: 1874-1881.
56. Manikwar, P, Büyüktimkin, B, Kiptoo, P, Badawi, AH, Galeva, NA, Williams, TD et al. (2012). I-domain-antigen conjugate (IDAC) for delivering antigenic peptides to |APC: synthesis, characterization, and in vivo EAE suppression. Bioconjug Chem 23: 509-517.
57. Brod, SA, Marshall, GD Jr, Henninger, EM, Sriram, S, Khan, M and Wolinsky, JS (1996). Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 46: 1633-1638.
58. Neurath, MF and Finotto, S (2011). IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89.
59. Kiessling, LL (2010). Decoding signals with chemical biology. ACS Chem Biol 5: 1-2.
60. Puffer, EB, Pontrello, JK, Hollenbeck, JJ, Kink, JA and Kiessling, LL (2007). Activating B cell signaling with defined multivalent ligands. ACS Chem Biol 2: 252-262.